"GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Holmes-jr, DR" . "Jak l\u00E9\u010Dit nemocn\u00E9 s infarktem myokardu s elevacemi ST a nemoc\u00ED v\u00EDce tepen?" . . "2"^^ . "32" . "1"^^ . . . "I, Z(MSM0021620817)" . "Jak l\u00E9\u010Dit nemocn\u00E9 s infarktem myokardu s elevacemi ST a nemoc\u00ED v\u00EDce tepen?"@cs . . "[EE0288261530]" . . "European Heart Journal" . . . . . "Over 50% of ST-segment elevation myocardial infarction (STEMI) patients suffer multi-vessel coronary artery disease, which is known to be associated with worse prognosis. Treatment strategies used in clinical practice vary from acute multi-vessel percutaneous coronary intervention (PCI), through staged PCI procedures to a conservative approach with primary PCI of only the infarct-related artery (IRA) and subsequent medical therapy unless recurrent ischaemia occurs. Each approach has advantages and disadvantages. This review paper summarizes the international experience and authors\u00B4 opinion on this clinically important question. Multi-vessel disease in STEMI is not a single entity and thus the treatment approach should be individualized. However, the following general rules can be proposed till future large randomized trials prove otherwise: (i) Single-vessel acute PCI should be the default strategy (to treat only the IRA during the acute phase of STEMI). (ii) Acute multi-vessel PCI can be justified only in exceptional patients with multiple critical (>90%) and potentially unstable lesions. (iii) Significant lesions of the non-infarct arteries should be treated either medically or by staged revascularization procedures-both options are currently acceptable."@en . "4" . . . "How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?"@en . "How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?"@en . "V\u00EDce ne\u017E 50% pacient\u016F s infarktem myokardu s elevacemi ST (STEMI) m\u00E1 nemoc v\u00EDce tepen, kter\u00E1 je sdru\u017Eena s hor\u0161\u00ED progn\u00F3zou. L\u00E9\u010Debn\u00E9 strategie v t\u011Bchto p\u0159\u00EDpadech kol\u00EDsaj\u00ED mezi perkut\u00E1nn\u00ED koron\u00E1rn\u00ED intervenc\u00ED (PCI) v\u00EDce tepen nebo konzervativn\u00ED p\u0159\u00EDstupem pouze s PCI infarktov\u00E9 tepny. Ka\u017Ed\u00FD p\u0159\u00EDstup m\u00E1 sv\u00E9 v\u00FDhody a nev\u00FDhody. Souhrnn\u00E1 pr\u00E1ce autor\u016F sumarizuje n\u00E1zor autor\u016F na tuto d\u016Fle\u017Eitou ot\u00E1zku. Nemoc v\u00EDce tepen u STEMI nen\u00ED jednotn\u00E1 choroba, proto l\u00E9\u010Dba mus\u00ED b\u00FDt individualizovan\u00E1. N\u00E1sleduj\u00EDc\u00ED pravidla byla navr\u017Eena pro budouc\u00ED velk\u00E9 randomizovan\u00E9 studie: (i)P\u0159i nemoci jedn\u00E9 tepny je PCI jednoznanou terapi\u00ED (l\u00E9\u010D\u00ED se pouze infarktov\u00E1 tepna b\u011Bhem akutn\u00ED f\u00E1ze STEMI), (ii)Akutn\u00ED v\u00EDce\u010Detn\u00E1 PCI je zd\u016Fvodn\u011Bna pouze vyj\u00EDme\u010Dn\u011B u pacient\u016F s mnoho\u010Detn\u00FDmi kritick\u00FDmi l\u00E9zemi (nad 90%) potenci\u00E1ln\u011B nestabiln\u00EDmi, (iii)V\u00FDznamn\u00E9 l\u00E9ze neinfarktov\u00FDch tepen by mohly b\u00FDt l\u00E9\u010Deny jak farmaky, tak revakulariza\u010Dn\u00EDmi z\u00E1kroky - oba p\u0159\u00EDstupy jsou akceptabiln\u00ED."@cs . "V\u00EDce ne\u017E 50% pacient\u016F s infarktem myokardu s elevacemi ST (STEMI) m\u00E1 nemoc v\u00EDce tepen, kter\u00E1 je sdru\u017Eena s hor\u0161\u00ED progn\u00F3zou. L\u00E9\u010Debn\u00E9 strategie v t\u011Bchto p\u0159\u00EDpadech kol\u00EDsaj\u00ED mezi perkut\u00E1nn\u00ED koron\u00E1rn\u00ED intervenc\u00ED (PCI) v\u00EDce tepen nebo konzervativn\u00ED p\u0159\u00EDstupem pouze s PCI infarktov\u00E9 tepny. Ka\u017Ed\u00FD p\u0159\u00EDstup m\u00E1 sv\u00E9 v\u00FDhody a nev\u00FDhody. Souhrnn\u00E1 pr\u00E1ce autor\u016F sumarizuje n\u00E1zor autor\u016F na tuto d\u016Fle\u017Eitou ot\u00E1zku. Nemoc v\u00EDce tepen u STEMI nen\u00ED jednotn\u00E1 choroba, proto l\u00E9\u010Dba mus\u00ED b\u00FDt individualizovan\u00E1. N\u00E1sleduj\u00EDc\u00ED pravidla byla navr\u017Eena pro budouc\u00ED velk\u00E9 randomizovan\u00E9 studie: (i)P\u0159i nemoci jedn\u00E9 tepny je PCI jednoznanou terapi\u00ED (l\u00E9\u010D\u00ED se pouze infarktov\u00E1 tepna b\u011Bhem akutn\u00ED f\u00E1ze STEMI), (ii)Akutn\u00ED v\u00EDce\u010Detn\u00E1 PCI je zd\u016Fvodn\u011Bna pouze vyj\u00EDme\u010Dn\u011B u pacient\u016F s mnoho\u010Detn\u00FDmi kritick\u00FDmi l\u00E9zemi (nad 90%) potenci\u00E1ln\u011B nestabiln\u00EDmi, (iii)V\u00FDznamn\u00E9 l\u00E9ze neinfarktov\u00FDch tepen by mohly b\u00FDt l\u00E9\u010Deny jak farmaky, tak revakulariza\u010Dn\u00EDmi z\u00E1kroky - oba p\u0159\u00EDstupy jsou akceptabiln\u00ED." . "Widimsk\u00FD, P." . "Acute myocardial infarction, Multi-vessel disease, Primary percutaneous coronary intervention"@en . . "Jak l\u00E9\u010Dit nemocn\u00E9 s infarktem myokardu s elevacemi ST a nemoc\u00ED v\u00EDce tepen?" . "8"^^ . "206079" . "RIV/00064173:_____/11:#0000108" . . "RIV/00064173:_____/11:#0000108!RIV12-MZ0-00064173" . "Jak l\u00E9\u010Dit nemocn\u00E9 s infarktem myokardu s elevacemi ST a nemoc\u00ED v\u00EDce tepen?"@cs . . . "0195-668X" . . .